Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | CCR2 | P41597 | 4/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5328599 | 0.91 | DRD2 (0.51) | DRD2SLC18A3TAAR1CCR2 | |
| SCHEMBL5326193 | 0.82 | DRD2 (0.51) | DRD2CHRM4SLC18A3CCR2OPRM1 | |
| SCHEMBL5462617 | 0.79 | DRD2 (0.54) | DRD2SLC18A3TAAR1KDM1A | |
| SCHEMBL5458686 | 0.78 | ALDH1A1 (0.50) | DRD2CHRM4ALDH1A1KDM4E | |
| SCHEMBL5323533 | 0.76 | DRD2 (0.49) | DRD2SLC18A3CCR2OPRM1ALDH1A1 | |
| SCHEMBL5459675 | 0.74 | CCR2 (0.56) | CCR2ALDH1A1RAB9A | |
| SCHEMBL14387014 | 0.74 | CCR2 (0.56) | CCR2ALDH1A1RAB9A | |
| SCHEMBL5322776 | 0.72 | CCR2 (0.46) | DRD2SLC18A3CCR2OPRM1HSD11B1 | |
| SCHEMBL14386913 | 0.71 | CCR2 (0.73) | CCR2ALDH1A1RAB9A | |
| SCHEMBL14386851 | 0.71 | CCR2 (0.55) | CCR2ALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197590-A1 | SUBSTITUTED DIPIPERIDINE CCR2 ANTAGONISTS | JANSSEN PHARMACEUTCA N.V. (BE) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197590-A1 | SUBSTITUTED DIPIPERIDINE CCR2 ANTAGONISTS | CCR2, CCR1, CCR5 | DRD2 284/4885CHRM4 3792/4885SLC18A3 4056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.